We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial

News   Feb 01, 2012

 
Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial
 
 
Advertisement
 

RELATED ARTICLES

mRNA COVID-19 Vaccine Is Well-Tolerated and Generates Immune Response

News

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

READ MORE

Large Study Finds HPV Vaccine Is Effective Against Cervical Cancer

News

Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. That is according to a large study by researchers at Karolinska Institutet in Sweden.

READ MORE

New Cancer Drug Targeting DNA Repair Shows Promise in Early-Stage Trial

News

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE